Celcuity shares are trading higher after the company announced it will disclosed the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.
Celcuity shares are trading higher after the company announced it will disclosed the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.